Last updated: July 18, 2026
ALLEGRA-D 12 HOUR (fexofenadine-pseudoephedrine) investment scenario and fundamentals analysis: patent, exclusivity, FDA status, and competitive outlook
Executive summary: ALLEGRA-D 12 HOUR (fexofenadine hydrochloride 12-hour extended release plus pseudoephedrine hydrochloride 12-hour extended release) is an OTC combination product in the US with an established, commoditized competitive set. From an IP and regulatory standpoint, the product is not dependent on biologics exclusivity and does not hinge on a single protected “blockbuster” patent estate like prescription specialty drugs. Investment fundamentals therefore skew to distribution, formulation/manufacturing execution, price-volume management, and payer-free consumer demand stability, rather than long-dated exclusivity capture. Key risk is that the combination’s market economics are exposed to low switching costs and persistent generic and private-label pressure.
What is ALLEGRA-D 12 HOUR and what are the key commercial drivers for investors?
Product definition. ALLEGRA-D 12 HOUR is an OTC allergy and congestion combination using:
- Fexofenadine HCl (second-generation antihistamine)
- Pseudoephedrine HCl (oral decongestant) in a 12-hour extended-release format
(Drug label and OTC product packaging describe the actives and dosing schedule.) [1]
Core demand drivers
- Seasonality and geography. Demand spikes track allergic rhinitis seasons and regional pollen cycles in the US.
- Consumer channel mix. Sales depend on:
- mass retail and club pharmacies
- e-commerce and subscription promos
- convenience channels during peak periods
- Price elasticity. Combination products typically face faster substitution when shelf prices diverge from generics or store brands.
- Regulatory “availability” friction. Pseudoephedrine OTC supply and retail controls affect in-store conversion and substitution toward in-channel alternatives. US requirements for pseudoephedrine sales and recordkeeping influence store operations. [2]
- Form factor preference. 12-hour extended release can improve convenience relative to multiple daily dosing competitors, but it does not stop generic penetration.
Investor-relevant implication: For ALLEGRA-D 12 HOUR, upside typically comes from share gains during peak season and stable gross margin via supply reliability and trade spend discipline, not from new exclusivity events.
What is the FDA regulatory status of ALLEGRA-D 12 HOUR, and what does that mean for exclusivity?
FDA category and pathway. ALLEGRA-D 12 HOUR is an OTC drug. OTC marketing authorizations rely on OTC drug monograph and/or NDA/ANDA routes depending on the active and formulation history, with OTC combination products typically supported by established regulatory review and labeling.
Practical exclusivity framing for investors (US):
- The presence of a long-established antihistamine (fexofenadine) and long-established decongestant (pseudoephedrine) generally reduces the probability of strong long-duration “remaining exclusivity” as a commercial moat.
- For small-molecule OTC combinations, the relevant constraints are usually labeling, formulation-specific protections (if any), and brand-level market positioning, not biologics-style data exclusivity.
Regulatory pseudoephedrine constraints matter for supply and retail execution. US federal oversight includes retail sales controls due to diversion risks, including transaction records and limits. [2]
Investor implication: If you underwrite margins, underwrite operational consistency (OTC retail compliance, supply continuity, pack configuration) and competition-based price floors, not patent-only durability.
What is the Orange Book status of ALLEGRA-D 12 HOUR?
Orange Book relevance. The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) lists approved prescription drugs and certain OTC products when they are approved under NDAs/ANDAs and have patent protections tied to approval. For a specific OTC combination, the Orange Book listing can be incomplete from a market perspective if the product is marketed without a listing that is tied to a prescription approval record.
Investment takeaway (IP strategy, not legal detail):
- Even when Orange Book listings exist, the practical investor view for a matured OTC combination is that generic and private label penetration already exists or is readily supportable if patents are expired or weak.
- Patent enforceability for OTC combos often depends on formulation and method-specific claims, which can be designed around.
Because a reliable, product-specific Orange Book entry set for “ALLEGRA-D 12 HOUR” is not provided in the prompt, this analysis does not assert a specific Orange Book patent list or expiration dates for that exact SKU.
What patents protect fexofenadine-pseudoephedrine combination products in the US?
How to think about patent protection for this class
For fexofenadine + pseudoephedrine combinations, patent estates typically cluster into:
- Controlled release or extended-release formulation for one or both actives.
- Specific dosage forms and excipient systems enabling 12-hour release.
- Manufacturing methods for the extended-release matrix or coating.
- Combinations/kit packaging claims, less common as enforceable protection when composition is obvious from prior art.
- Method-of-use claims (antiallergy with congestion) often weaken because the actives’ clinical use is well established.
Investor implication: Even if some formulation patents remain, market economics often still degrade due to:
- generic design-around
- minor formulation tweaks
- switching between alternative combo brands (or single-active OTC switching)
When does ALLEGRA-D 12 HOUR lose exclusivity or face generic entry risk in the US?
Exclusivity risk framework
- For matured OTC combination products, the “generic entry risk” usually reflects whether any remaining formulation or manufacturing patents cover the specific extended-release performance characteristics and whether those patents are enforceable against potential ANDA-type approvals or OTC equivalent formulations.
Commercial reality check
- Even where a brand has patents, OTC market penetration can continue through:
- authorized generics
- private label equivalents
- reformulated equivalents with different release profiles or excipients (if legally and physically feasible)
- With pseudoephedrine-specific retail controls already present, availability and stocking cycles can temporarily advantage particular brands, but it is not a structural barrier.
Investor implication: Underwriting should assume that competition persists rather than treating exclusivity as a multi-year margin shield.
How strong is the patent estate for ALLEGRA-D 12 HOUR and how does it compare with generic and private-label threats?
Strength assessment for matured OTC combos (practical investment lens)
- For mature actives, patent estates tend to be:
- narrow (formulation or process specific)
- expired or close to expiry in key jurisdictions
- subject to design-around
- This usually yields a litigation/enforcement profile that does not stop the market from filling with substitutes.
Competitive consequences
- Generic/private label products often compete on:
- price-per-dose
- shelf familiarity
- promo depth and retailer placement
- extended-release equivalence claims
Investor implication: Patent strength typically supports short-term shelf differentiation, not long-term category control.
What generic entry risks exist for fexofenadine-pseudoephedrine extended-release 12-hour OTC products?
Primary entry pathways
- Compounding substitutes at the retail level is unlikely at scale for exact extended-release behavior.
- Market entry typically occurs via:
- OTC equivalent products manufactured to meet labeled dose and performance
- authorized generics or private label arrangements
- incremental formulation changes that maintain similar clinical effect
Why risk remains elevated
- Switching costs for consumers are low.
- Retail shelf space is the gating factor.
- Peak-season demand can pull competitors into the category quickly.
Investor implication: Any investment thesis should treat market share as contestable each season rather than sticky due to consumer brand loyalty alone.
What patent litigation affects ALLEGRA-D 12 HOUR or its combination competitors?
Litigation risk for matured OTC combos
- When there is active litigation, it typically targets:
- extended-release formulation claims
- process claims related to manufacturing
- enforcement around label or composition adherence
- Settlement agreements commonly result in:
- delayed launches for specific strengths or release profiles
- licensing or covenant structures
- design-around permission
Constraint on this analysis
No case list or dockets were provided in the prompt, and no product-specific litigation record is included here. This response therefore does not enumerate lawsuits, settlement dates, or involved patent numbers.
What settlement agreements and licensing deals matter for the ALLEGRA-D competitive landscape?
Practical deal types in OTC combos
- settlement-for-delay between brand and generic applicants
- coexistence agreements if formulation differences are material
- supply agreements where a generic party manufactures product for a brand under brand label
Constraint
No licensing or settlement terms were provided. This response therefore does not assert specific agreements, parties, or dates.
Which companies compete with ALLEGRA-D 12 HOUR in allergy and congestion OTC, and how do they position?
Competitive set (category view)
- Other antihistamine + decongestant combo brands
- Private label versions in mass retail
- Single-active alternatives:
- antihistamines without decongestants
- decongestants without antihistamines
These reduce share when the combination price rises relative to substitutes.
Investor implication: Competitive positioning is mainly:
- promo intensity during peak months
- channel-specific pricing
- perceived equivalence in “works fast” and “lasts 12 hours” claims
(Company-specific lists are omitted because a reliable, source-backed competitor roster for ALLEGRA-D 12 HOUR by SKU is not provided in the prompt.)
How does ALLEGRA-D 12 HOUR compare with other allergy + congestion OTC options on price, efficacy perception, and switching?
Switching logic
- If consumers feel an antihistamine alone is sufficient, they switch away from the decongestant bundle.
- If congestion dominates, they may switch to decongestant-only products or nasal decongestants, depending on preference and contraindications.
What investors should underwrite
- net price after trade and retailer allowances
- promo elasticity (how much volume lift comes at what margin cost)
- SKU mix within 12-hour formats (pack size and dosing convenience)
Investor implication: Any margin upside depends on limiting promotional leakage while sustaining peak-season conversion.
What are the manufacturing and IP barriers for making extended-release fexofenadine-pseudoephedrine?
Barriers that matter in practice
- validated extended-release performance (12-hour release profile)
- stability and bioequivalence for the exact active strengths
- compliance with cGMP and OTC quality specs
- excipient system and coating/matrix know-how
Design-around reality
- Even if specific patents are narrow, scale manufacturing know-how can be a barrier for smaller entrants.
- Larger generic players can usually replicate the supply chain quickly if the legal barriers are cleared.
Investor implication: Manufacturing excellence supports margin and supply continuity but does not eliminate competition.
Where is revenue exposure concentrated for ALLEGRA-D 12 HOUR and what risks drive downside?
Revenue exposure (typical for seasonal OTC)
- concentrated in short windows (allergy season)
- concentrated in retailers that control shelf space and promotional mechanics
- concentrated among consumers seeking congestion relief plus antihistamine benefit
Downside risks
- Price compression from generics/private label.
- Trade spend increase to hold shelf position.
- Supply disruptions affecting peak season availability.
- Regulatory enforcement friction at retail for pseudoephedrine controls leading to stockouts or reduced conversion. [2]
- Consumer substitution to single-active products or alternative combos.
Investor implication: The risk profile is operational and commercial rather than patent-driven.
Key Takeaways
- ALLEGRA-D 12 HOUR is a mature OTC combination built on established actives; its investment durability depends more on seasonal execution, channel economics, and supply reliability than on long-lived exclusivity.
- Patent and litigation dynamics for mature extended-release OTC combos are usually narrow and design-aroundable, which supports a steady competitive threat.
- Pseudoephedrine’s US retail controls are a structural variable that affects availability and conversion during peak demand. [2]
- Underwrite downside to price-volume erosion from generics and private label, and to promo inflation needed to defend shelf share.
FAQs
1) Does ALLEGRA-D 12 HOUR have the same exclusivity protections as prescription drugs?
No. As an OTC combination product, the commercial moat is typically driven by formulation execution and brand positioning rather than prescription-style exclusivity.
2) How do pseudoephedrine retail controls affect brand sales during allergy season?
They can reduce in-store conversion when compliance processes slow sales or when retailers restrict access, increasing substitution and stockout risk. [2]
3) What formulation factors determine whether an extended-release generic can compete?
Release profile, stability, excipient/coating or matrix design, and ability to meet labeled performance and quality requirements.
4) Is patent litigation likely to stop competition for ALLEGRA-D 12 HOUR-style products?
In matured OTC combinations, litigation rarely prevents category competition long-term; it more often delays specific designs or launches.
5) What is the biggest investment swing factor for OTC allergy and congestion products?
Net realized pricing after trade plus promo intensity during peak season, with supply continuity and retail availability as the operational gate.
References (APA)
- ALLEGRA-D 12 HOUR. Prescribing information and product labeling (active ingredients and dosing schedule).
- US federal requirements for pseudoephedrine retail sales controls (Combat Methamphetamine Epidemic Act and related CFR guidance).
